Cargando…

Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects

Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanboonkunupakarn, Borimas, Ashley, Elizabeth A., Jittamala, Podjanee, Tarning, Joel, Pukrittayakamee, Sasithon, Hanpithakpong, Warunee, Chotsiri, Palang, Wattanakul, Thanaporn, Panapipat, Salwaluk, Lee, Sue J., Day, Nicholas P. J., White, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249579/
https://www.ncbi.nlm.nih.gov/pubmed/25267661
http://dx.doi.org/10.1128/AAC.03704-14
_version_ 1782346862595932160
author Hanboonkunupakarn, Borimas
Ashley, Elizabeth A.
Jittamala, Podjanee
Tarning, Joel
Pukrittayakamee, Sasithon
Hanpithakpong, Warunee
Chotsiri, Palang
Wattanakul, Thanaporn
Panapipat, Salwaluk
Lee, Sue J.
Day, Nicholas P. J.
White, Nicholas J.
author_facet Hanboonkunupakarn, Borimas
Ashley, Elizabeth A.
Jittamala, Podjanee
Tarning, Joel
Pukrittayakamee, Sasithon
Hanpithakpong, Warunee
Chotsiri, Palang
Wattanakul, Thanaporn
Panapipat, Salwaluk
Lee, Sue J.
Day, Nicholas P. J.
White, Nicholas J.
author_sort Hanboonkunupakarn, Borimas
collection PubMed
description Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (C(max)), area under the concentration-time curve from 0 h to the end of the study (AUC(0–last)), and area under the concentration-time curve from 0 h to infinity (AUC(0–∞)) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.)
format Online
Article
Text
id pubmed-4249579
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-42495792014-12-31 Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects Hanboonkunupakarn, Borimas Ashley, Elizabeth A. Jittamala, Podjanee Tarning, Joel Pukrittayakamee, Sasithon Hanpithakpong, Warunee Chotsiri, Palang Wattanakul, Thanaporn Panapipat, Salwaluk Lee, Sue J. Day, Nicholas P. J. White, Nicholas J. Antimicrob Agents Chemother Clinical Therapeutics Dihydroartemisinin-piperaquine is an artemisinin-based combination treatment (ACT) recommended by the WHO for uncomplicated Plasmodium falciparum malaria, and it is being used increasingly for resistant vivax malaria where combination with primaquine is required for radical cure. The WHO recently reinforced its recommendations to add a single dose of primaquine to ACTs to reduce P. falciparum transmission in low-transmission settings. The pharmacokinetics of primaquine and dihydroartemisinin-piperaquine were evaluated in 16 healthy Thai adult volunteers in a randomized crossover study. Volunteers were randomized to two groups of three sequential hospital admissions to receive 30 mg (base) primaquine, 3 tablets of dihydroartemisinin-piperaquine (120/960 mg), and the drugs together at the same doses. Blood sampling was performed over 3 days following primaquine and 36 days following dihydroartemisinin-piperaquine dosing. Pharmacokinetic assessment was done with a noncompartmental approach. The drugs were well tolerated. There were no statistically significant differences in dihydroartemisinin and piperaquine pharmacokinetics with or without primaquine. Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (C(max)), area under the concentration-time curve from 0 h to the end of the study (AUC(0–last)), and area under the concentration-time curve from 0 h to infinity (AUC(0–∞)) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively. This interaction is similar to that described recently with chloroquine and may result in an enhanced radical curative effect. (This study has been registered at ClinicalTrials.gov under registration no. NCT01525511.) American Society for Microbiology 2014-12 /pmc/articles/PMC4249579/ /pubmed/25267661 http://dx.doi.org/10.1128/AAC.03704-14 Text en Copyright © 2014 Hanboonkunupakarn et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 3.0 Unported license (http://creativecommons.org/licenses/by/3.0/) .
spellingShingle Clinical Therapeutics
Hanboonkunupakarn, Borimas
Ashley, Elizabeth A.
Jittamala, Podjanee
Tarning, Joel
Pukrittayakamee, Sasithon
Hanpithakpong, Warunee
Chotsiri, Palang
Wattanakul, Thanaporn
Panapipat, Salwaluk
Lee, Sue J.
Day, Nicholas P. J.
White, Nicholas J.
Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title_full Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title_fullStr Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title_full_unstemmed Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title_short Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
title_sort open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects
topic Clinical Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249579/
https://www.ncbi.nlm.nih.gov/pubmed/25267661
http://dx.doi.org/10.1128/AAC.03704-14
work_keys_str_mv AT hanboonkunupakarnborimas openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT ashleyelizabetha openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT jittamalapodjanee openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT tarningjoel openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT pukrittayakameesasithon openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT hanpithakpongwarunee openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT chotsiripalang openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT wattanakulthanaporn openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT panapipatsalwaluk openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT leesuej openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT daynicholaspj openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects
AT whitenicholasj openlabelcrossoverstudyofprimaquineanddihydroartemisininpiperaquinepharmacokineticsinhealthyadultthaisubjects